Chen Lijun, Wu Qiaoyuan, Fu Jia, Jiang Mengjie, Qiu Jialin, Tao Jiaomei, Lin Litong, Chen Shenshen, Wu Yi, Yang Zhengqiang, Li Jianxu, Liang Shixiong
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Oncol. 2024 Sep 2;14:1371409. doi: 10.3389/fonc.2024.1371409. eCollection 2024.
Radiotherapy (RT) plays an important role in the treatment of hepatocellular carcinoma (HCC). To screen patients who benefit most from RT, a nomogram for survival prediction of RT based on a large sample of patients with HCC was created and validated.
A total of 2,252 cases collected from the Surveillance, Epidemiology, and End Results (SEER) database were separated into a training or an internal validation cohort in a 7:3 ratio ( = 1,565:650). An external validation cohort of cases from our institute was obtained ( = 403). LASSO regression and Cox analyses were adopted to develop a nomogram for survival prediction. The decision curve analysis (DCA), calibration curve, and time-dependent receiver operating characteristic curves (TROCs) demonstrated the reliability of the predictive model.
For patients with HCC who received RT, the analyses revealed that the independent survival prediction factors were T stage {T2 vs. T1, hazard ratio (HR) =1.452 [95% CI, 1.195-1.765], < 0.001; T3 vs. T1, HR = 1.469 [95% CI, 1.168-1.846], < 0.001; T4 vs. T1, HR = 1.291 [95% CI, 0.951-1.754], = 0.101}, N stage (HR = 1.555 [95% CI, 1.338-1.805], < 0.001), M stage (HR = 3.007 [95% CI, 2.645-3.418], < 0.001), max tumor size (>2 and ≤5 vs. ≤2 cm, HR = 1.273 [95% CI, 0.992-1.633], = 0.057; >5 and ≤10 vs. ≤2 cm, HR = 1.625 [95% CI, 1.246-2.118], < 0.001; >10 vs. ≤2 cm, HR = 1.784 [95% CI, 1.335-2.385], < 0.001), major vascular invasion (MVI) (HR = 1.454 [95% CI, 1.028-2.057], = 0.034), alpha fetoprotein (AFP) (HR = 1.573 [95% CI, 1.315-1.882], < 0.001), and chemotherapy (HR = 0.511 [95% CI, 0.454-0.576], < 0.001). A nomogram constructed with these prognostic factors demonstrated outstanding predictive accuracy. The area under the curve (AUC) in the training cohort for predicting overall survival (OS) at 6, 12, 18, and 24 months was 0.824 (95% CI, 0.803-0.846), 0.824 (95% CI, 0.802-0.845), 0.816 (95% CI, 0.792-0.840), and 0.820 (95% CI, 0.794-0.846), respectively. The AUCs were similar in the other two cohorts. The DCA and calibration curve demonstrated the reliability of the predictive model.
For patients who have been treated with RT, a nomogram constructed with T stage, N stage, M stage, tumor size, MVI, AFP, and chemotherapy has good survival prediction ability.
放射治疗(RT)在肝细胞癌(HCC)治疗中发挥着重要作用。为筛选出从RT中获益最大的患者,基于大量HCC患者样本创建并验证了一个用于RT生存预测的列线图。
从监测、流行病学和最终结果(SEER)数据库收集的2252例病例按7:3的比例分为训练队列或内部验证队列(n = 1565:650)。获取了来自本研究所的病例外部验证队列(n = 403)。采用LASSO回归和Cox分析来开发用于生存预测的列线图。决策曲线分析(DCA)、校准曲线和时间依赖性受试者工作特征曲线(TROCs)证明了预测模型的可靠性。
对于接受RT的HCC患者,分析显示独立的生存预测因素为T分期{T2 vs. T1,风险比(HR)= 1.452 [95% CI,1.195 - 1.765],P < 0.001;T3 vs. T1,HR = 1.469 [95% CI,1.168 - 1.846],P < 0.001;T4 vs. T1,HR = 1.291 [95% CI,0.951 - 1.754],P = 0.101}、N分期(HR = 1.555 [95% CI,1.338 - 1.805],P < 0.001)、M分期(HR = 3.007 [95% CI,2.645 - 3.418],P < 0.001)、最大肿瘤大小(>2且≤5 vs. ≤2 cm,HR = 1.273 [95% CI,0.992 - 1.633],P = 0.057;>5且≤10 vs. ≤2 cm,HR = 1.625 [95% CI,1.246 - 2.118],P < 0.001;>10 vs. ≤2 cm,HR = 1.784 [95% CI,1.335 - 2.385],P < 0.001)、主要血管侵犯(MVI)(HR = 1.454 [95% CI,1.028 - 2.057],P = 0.034)、甲胎蛋白(AFP)(HR = 1.573 [95% CI,1.315 - 1.882],P < 0.001)以及化疗(HR = 0.511 [95% CI,0.454 - 0.576],P < 0.001)。用这些预后因素构建的列线图显示出出色的预测准确性。训练队列中预测6、12、18和24个月总生存(OS)的曲线下面积(AUC)分别为0.824(95% CI,0.803 - 0.846)、0.824(95% CI,0.802 - 0.845)、0.816(95% CI,0.792 - 0.840)和0.820(95% CI,0.794 - 0.846)。其他两个队列中的AUC相似。DCA和校准曲线证明了预测模型的可靠性。
对于接受RT治疗的患者,用T分期、N分期、M分期、肿瘤大小、MVI、AFP和化疗构建的列线图具有良好的生存预测能力。